Asymchem
Asymchem is a CDMO brand whose official website describes it as a provider for global pharmaceutical companies.
Last updated October 9, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Asymchem is presented on its official website as a CDMO serving global pharmaceutical companies. The website homepage uses the headline “Asymchem: Top CDMO for Global Pharma Companies.” The supplied site text also identifies Asymchem Inc. as the website’s data controller, publisher, owner, and operator. The available evidence does not specify the company’s founding date, headquarters, founder, ownership beyond the website’s stated role, named executives, product portfolio, or geographic operating footprint.
History
The supplied evidence identifies Asymchem through its official website and the homepage headline “Asymchem: Top CDMO for Global Pharma Companies.” It therefore supports describing the brand as a CDMO serving global pharmaceutical companies. The website’s supplied privacy-policy text names Asymchem Inc. as the data controller and states that it is the publisher, owner, and operator of the website. The available material does not provide a company founding date or founding story, a headquarters location, details of ownership or corporate structure beyond that website role, named leadership, or a chronology of business developments. No dated milestones can be established from the supplied evidence.
- 2021
Secondary listing on the Hong Kong Stock Exchange (ticker 06821).
- 2016
Initial public offering on the Shenzhen Stock Exchange (ticker 002821).
- 1998
Asymchem founded in Tianjin, China by Dr. Hao Hong.
Products and positioning
The official website positions Asymchem as a CDMO for global pharmaceutical companies.
Small-molecule APIs
Active pharmaceutical ingredients for small-molecule drugs.
Advanced intermediates
Complex chemical intermediates for drug synthesis.
Drug products
Finished dosage forms for clinical and commercial use.
CDMO services
Integrated development and manufacturing services from preclinical to commercial.
Recent events
Asymchem to acquire Snapdragon Chemistry[2]
Reported:
Snapdragon Chemistry announced its proposed acquisition by Asymchem; the deal was expected to close in the second quarter of 2022, pending regulatory approval.
Hillhouse Capital and Asymchem reach strategic cooperation[3]
Reported:
Hillhouse Capital and Asymchem reached a strategic cooperation, with Hillhouse Capital committing to bring Asymchem at least 800 million yuan in orders.
Kaileying announces a RMB 2.3 billion private placement subscription with Hillhouse Capital[4]
Reported:
On the evening of February 16, 2020, Kaileying announced a RMB 2.3 billion private placement plan fully subscribed by Hillhouse Capital, replacing its previously planned fundraising for biologic drug CDMO and formulation-facility expansion. The new fundraising was stated to be used in full, after issuance expenses, to replenish working capital.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/asymchem · Editorial policy · How profiles are compiled